Combined modality treatment for patients with stage IV melanoma: Cyclophosphamide and a dendritic cell vaccine loaded with killed allogeneic melanoma cells
Phase 1
- Conditions
- melanoma
- Registration Number
- JPRN-UMIN000004617
- Lead Sponsor
- Department of Hematology and Oncology, Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with a history of neoplasitic disease other than melanoma within 5 years 2. Patients with a history of autoimmune disease 3. Patients with unstable angina pectoris, congestive heart failure, asthma or active systemic infection 4. Positive for HBs Ag, HCV Ab, HTLV-I Ab, HIV Ab, or serological test for syphilis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method